With the 2025 AI Observatory report, EMA and HMA capture a transformation that is already under way: artificial intelligence is being discussed with companies across increasingly broad areas of the medicinal product lifecycle and, at the same time, is being adopted by regulatory authorities to improve efficiency, document analysis and decision-making capacity. In parallel, the European AI Act, EMA/FDA guidance and the workplan on data and AI are defining a new frame of reference.

The global Healthcare BPO market is expected to grow significantly by 2030. Yet the economic figure tells only part of the story. The real transformation lies in how pharma and life sciences companies are redefining the relationship between internal capabilities, external partners, digital technologies and process governance.

A novelty in the world of biomaterials

Genenta announces Long-Term follow-up observations in brain tumor (GBM) study with emerging survival signals

A Special Issue of MakingPharmaIndustry Magazine dedicated to the 65th AFI Symposium explores the transformations shaping the pharmaceutical supply chain in the age of artificial intelligence, across innovation, quality, regulatory affairs, research, manufacturing and new skills.

This special issue explores the impact of automation and AI on pharmaceutical production—across GxP, sustainability, and digitalization.